AstraZeneca and Daiichi Sankyo report updated results from phase II DESTINY-Breast01 trial of trastuzumab deruxtecan (Enhertu) in patients with HER2-positive metastatic breast cancer

Updated data demonstrated that patients who had received ≥2 prior HER2-based regimens treated with Enhertu achieved an objective response rate of 61.4%, median duration of response of 20.8 months and median progression-free survival of 19.4 months.

Source:

PharmaTimes